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Abstract
Background: Infections caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) are
considered to be important health problems worldwide. The purpose of this study was to measure
the general practitioners (GPs)' basic knowledge on HBV and HCV risk factors in determining their
practice about this subject.
Methods:  A cross-sectional type questionnaire survey was carried out at all of 32 primary
healthcare centers (PHCCs) in Samsun, Turkey, between March 1 and April 31, 2002. The
questionnaires were sent to 160 GPs and 129 (80.6%) of them answered the questionnaires.
Knowledge, role responsibility, self-efficacy and attitudes and beliefs regarding to viral hepatitis B
and hepatitis C were asked.
Results: Most of the GPs had adequate knowledge about transmission of HBV and HCV and also
about risk factors for transmission of viruses. Most of the GPs (83.7%) were aware of
recommendations for approach to a baby, born from HBsAg positive mother. They have limited
facilities in diagnosis of viral hepatitis. Of the participants, 108 (83.7%) expressed that they could
not diagnose HBV infections and 126 (97.7%) of them stated that they could not make the
diagnoses of HCV infection in their local healthcare centers. The knowledge about treatment of
chronic viral hepatitis B (21.8%) and C patients (17.8%) with elevated ALT is not sufficient.
Conclusion: GPs' knowledge about risks of viral hepatitis was adequate in this study. They were
not able to diagnose and follow up of these infections at PHCCs because of limited knowledge
about chronic viral hepatitis and diagnostic facilities. GPs should be informed about current advice
in diagnosis and treatment of chronic of HBV and HCV infections.
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Background
Infections caused by hepatitis B virus (HBV) and hepatitis
C virus (HCV) are important health problems worldwide
with a high morbidity and mortality [1-3]. It is known
that 400 million people are HBV carriers and that each
year 50 million people contact such a disease, resulting in
1–2 million deaths [3]. Infection with HCV occurs world-
wide, the prevalence of antibody against HCV (anti-HCV)
in serum in most developed countries range between 1%
to 2% [2]. It is also reported that currently 170 million
people all over the world are infected with HCV infections
and that 8000 – 10000 people die from HCV infection
and of complications per year [4,5]. Turkey, located in a
region with moderate risk, has a prevalence in a range of
1.0% to 2.4% [6]. The prevalence of HCV infection was
reported 1.5% in Turkey [7].
The hepatitis caused by HBV and HCV is extremely
obscure. Symptoms appear only in 35.0% of those
infected by HBV and in 25.0% of those infected by HCV.
However, HBV and HCV are highly transmittable. There-
fore, a decision made by World Health Organization
(WHO) and National Institute of Health (NIH) suggests
that all the patients should be examined with respect to
their risk factors for HCV [8]. Turkey falls into the
medium endemisity group in terms of HBV and HCV
infection prevalence [3,6]. Such infections develop with-
out any clear symptoms, so it is very important to carry
good performance by the GPs in terms of diagnosis, treat-
ment and follow up of patients. Therefore we attempted
to evaluate the current practices, knowledge, attitudes of
GPs regarding viral hepatitis B and C.
Methods
A cross-sectional study was carried out at all of 32 primary
healthcare centers (PHCCs) in the central district of Sam-
sun, Turkey between March 1 and April 31, 2002. The
questionnaires were sent to all GPs (n = 160). One hun-
dred and twenty-nine of 160 (83.7%) GPs from different
PHCCs completed the survey. The non-respondent GPs
randomly distributed in PHCCs. The questionnaire was
self-administered anonymously with an answer sheet.
Questionnaire [see Additional file 1]. Question format
ranged from closed questions with multiple choices to
open comment and true/false type. Demographic varia-
bles such as gender, age and practice period in PHCCs
were assessed. Also the information was collected regard-
ing diagnostic facilities at PHCCs. The survey question-
naire includes a multiple-choice question relevant to
sources of medical information. A question in medical
knowledge about transmission of hepatitis viruses
includes ten statements. GPs were asked to define these
statements as correct or incorrect. This question was all
marked out of 100. Ten points were given for each correct
choice the participants' marked and incorrect choice they
left untouched. Participants were asked: "What would you
suggest to do to protect an infant, born from a HBsAg pos-
itive mother?" The answers were: Injection of hepatitis B
vaccine and hepatitis B immunoglobulin (HBIG), offering
only hepatitis B vaccine, offering only HBIG, delivery by
caesarean section and no knowledge about the problem.
The participants were asked what they would suggest to do
to protect an infant, born from an anti-HCV and HCV
RNA positive mother with multi-choice question. The
answers were as follows: There is not any preventive meas-
ure, injection of immunoglobulin, delivery by caesarean
section, HCV does not transmit from mother to a baby
and no knowledge about the problem.
Clinical practice was evaluated with the questions in the
following: "What is the approximate number of individu-
als with acute or chronic viral hepatitis whom you diag-
nosed or followed up? Approximately how many
individuals with acute or chronic viral hepatitis have you
seen in the past 12 months?" Answers were obtained
using fill-in-the-blank spaces.
Current knowledge about patient management based on




A 35 years old woman with chronic hepatitis B admitted
to a primary health care center. Her serum alanine ami-
notransferase (ALT) level was normal.
Case-II
A 40 years old man has been positive for HBsAg (+) for
three years and two consecutive ALT results were 125 IU/
L and 120 IU/L, respectively.
Case-III
A healthy/asymptomatic 55 years-old man admitted to a
primary health care center. His alanine aminotransferase
(ALT) level was elevated (150 IU/L) during check-up for
life insurance; anti-HCV in ELISA was positive at subse-
quent work-up. He had a history of intravenous device
that he used in 1963.
Case-IV
A healthy/asymtomatic 32 years-old woman admitted to
a primary health care center. Her anti-HCV in ELISA was
positive blood donation and ALT level was normal at sub-
sequent work-up. She had no risk factors.
Shebab et al. [9] originally used the cases that were related
to HCV in a survey.BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/3
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GPs were asked: What their next step would be, which
additional test they would order, which treatment regi-
men they would recommend and if they would order a
therapy recommended by a specialist, in the view of these
cases.
In the text the results were given as means ± standard devi-
ations (SD).
Results
The questionnaire was completed anonymously, of the
160 surveys, 129 (83.7%) were received and investigated
using the data analysis.
Demographic characteristics
Of the study group, 72 (55.8%) GPs were women and 57
(44.2%) were men. The mean age of participants was 31.3
± 4.8 years. They had been in practice for 7.2 ± 4.6 years.
Knowledge about transmission of HBV and HCV
Blood transfusion (96.1%, 95.3%), blood and body fluids
(95.3%, 94. 6), sexual transmission (89.9%, 89.9%),
intravenous drug use (91.5%, 90.7%) and vertical trans-
mission (88.4%, 80.8) were listed as the most responsible
risk factors for HCV and HBV, respectively, by the GPs.
When the participants were asked about their suggestions
of how to protect an infant, born from a HBsAg positive
mother, it was stated by 108 (83.7%) of the participants
that Hepatitis B vaccine should be injected to the infant
during its delivery in addition to the immunoglobulin
therapy. Twenty (15.5%), 12 (9.3%), 7 (5.4%) and 7
(5.4%) are the number of the given answers in 129 GPs
for the following questions respectively; baby should be
taken out by caesarean section, only immunoglobulin
should be given at birth, only Hepatitis B vaccine should
be applied at birth and did not actually know what to do.
When the participants were asked about what they would
suggest do to protect an infant, born from an anti-HCV
and HCV RNA positive mother, it was stated by 67
(51.9%) of them that there were no preventive measures
to be taken during the birth and the baby should be fol-
lowed with respect to HCV infection. Thirty-four (26.4%),
33 (25.6%) and 7 (5.4%) of them suggested that immu-
noglobulin should be applied to the baby at birth, the
birth should be carried out by caesarean section, and they
aware not actually well informed about the case, respec-
tively. The participants could choose more than one solu-
tion regarding protection of baby from viral hepatitis.
Experience with viral hepatitis
GPs reported that they had no diagnostic laboratory tests
for HBV (108; 83.7%) and HCV (126; 97.7%). Because of
the lack of diagnostic laboratory tests, these diseases could
not be diagnosed at their PHCCs.
One hundred and ten (85.3%) of the participants
expressed that no patient with acute HBV (AHB) infection
admitted to their health care centers and 84 (65.1%) of
them stated that they did not encounter any patient with
chronic HBV (CHB) infection during the last 12 months.
Rest of 45 GPs encountered total 52 patients at previous
year; only 6 GPs examined more than one patient. One
hundred and twenty-six (97.7%) of them reported that
they did not encounter any patient with HCV infection.
Approach to sample cases
Table 1 shows the criteria used by the participants in the
management of the two cases with HBV infection.
Table 2 shows the criteria used by the participants in the
management of the two cases with HCV infection.
Sources of education
The answers given by the participants about the sources of
the updated current information for HBV and HCV infec-
tions were as follows, respectively: using journals: 63.6%,
52.7%, attending to congress: 14.0%, 11.6%, using books:
79.1%, 76.7% and on-line sites: 3.1%, 3.1% (The sum of
the answer is higher than the number of the participants
for the participants checked more than one item.)
Discussion
Our data suggest that, the high response rate to our ques-
tionnaire indicated that GPs find the problem as an
important area to consider. The sample was representative
of GPs in Samsun region. The results could be extrapo-
lated to whole Turkey on the basis of educational levels
and working conditions, although the practice years of the
respondents seem to be smaller than in practice.
HBV and HCV cause chronic viral hepatitis [10]. The fre-
quency of the HBV and HCV infections are high in devel-
oping countries, including Turkey, especially young
children who become infected with HBV are the most
likely to develop chronic infection [5,6,11]. Therefore,
GPs who constitute almost half of primary health care and
outpatient services are expected to know basic knowledge
on such infections. Furthermore, they are also supposed
to guide their patients appropriately in terms of analysis
of their diseases and treatment. GPs should be able to
identify HBV and HCV high-risk groups at an early period
because of the high importance of the complications like
cirrhosis and hepatic failure [6,9,12]. The majority of GPs
were well informed about transmission ways for HBV and
HCV. However they identified sexual and vertical trans-
mission as being important risk factors for HCV, the esti-
mated transmission risk is only 5% [13]. This indicatesBMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/3
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confusion between modes of transmission for HBV and
HCV. The relatively poorer levels of knowledge about
transmission of HCV obtained in this study may also be
found in the general population. Therefore strategic pro-
grammes of health education and awareness rising to
both professionals and public are recommended.
Up to 90% of infants of highly infected with HBsAg and
HBeAg positive mothers become HBV carriers compared
with 10% to 40% of babies born anti-HBe positive moth-
ers. HBV vaccine and HBIG should be applied at birth to
the baby born to a HBsAg positive mother [14]. Due to the
data gathered at the end of these studies the transmission
is not effected by the way of the baby delivery and breast-
feeding. Since the frequency of vertical transmission is less
than 5%, there was no special recommendation for anti-
HCV positive pregnant women [13,15,16]. This study
shows that most GPs are practicing within current recom-
mendations regarding hepatitis B immunization of
infants, but the use of vaccine and HBIG at birth may not
provide an effective safety in preventing perinatal HBV
transmission if screening for HBsAg is not performed uni-
versally. However most of them (83.7% and 97.7%,
respectively) were unable to diagnose the HBV and HCV
infections in PHCCs due to the lack of laboratory facili-
ties. Most of the participants pointed out that they had not
determined or followed up of any patient with HBV and
HCV infections at their health care centers during the last
12 months. This fact clearly shows that PHCCs in Turkey
are saw insufficient in terms of the determination of the
patients with HBV and HCV infections and their follow
up. These results underscore the need of effective mecha-
nisms in place and on time for immunoprophylaxis to
infants born to HBsAg positive women.
We identified gaps between the knowledge about appro-
priate use of diagnostic tests and interventions important
to identify patients with chronic hepatitis and to make
treatment decision. In case I; she has a normal ALT, HBV-
DNA testing and liver biopsy should not be recom-
mended [17,18]. However 61.2% of the respondents
ordered HBV DNA test and 72.1% liver biopsy in case I.
Forty-eight point one percent of the GPs stated HBV DNA
test and 34.1% liver biopsy in case II. The EASL consensus
statement recommended liver biopsy and consideration
for treatment in case II and regular follow up at six-month
interval with determination of ALT level, no further test-
ing to confirm the diagnosis of chronic HBV infection in
case I [17], but most of the participants did not differenti-
ate these two entities. In case III and IV, respondents
would unnecessarily repeat the anti-HCV test. These find-
ing suggest that inappropriate use of tests for viral hepati-
tis may lead to misdiagnosis, unnecessary testing, and also
over-treatment.
As long as ALT levels are normal, the treatment is not
required even if PCR HBV DNA or HCV RNA is found to
be positive [17,19]. However 41.8% and 37.2% of GPs
support to treat chronic hepatitis B and C patients with
normal ALT, respectively. When asked about the treat-
ment for HCV, only 17.8% of respondents recommended
combined interferon and ribavirin therapy to treat the
Table 1: Management of Patients with HBV
Case I Case II
n % Current Advice n % Current Advice
At this point your next step would be to:
Follow in clinic: level of ALT 53 41.1 Yes 19 14.7 No
Follow in clinic: refer if symptoms develop 43 33.3 Yes - - No
Refer to a specialist 29 22.5 No 10 7.6 Yes
Don't know 4 3.1 100 77.5
Which additional tests would you order 
(check all that apply)*:
HBV-DNA by PCR** 79 61.2 No 62 48.1 Yes
HBV genotyping 2 1.6 No 16 12.4 No
Liver biopsy 93 72.1 No 44 34.1 Yes
Don't know - - 2 1.6
If you order therapy, which regimen would 
you recommend:
Lamivudine 40 31.0 No 26 20.2 Yes
IFN-α + Lamivudine 3 2.3 No - - Yes
Interferon (IFN)-α 11 8.5 No 2 1.6 Yes
Don't know 75 58.2 101 78.2
* The sum of the answer is higher than the number of the participants for the participants checked more than one item. ** Polymerase Chain 
Reaction (PCR)BMC Gastroenterology 2004, 4 http://www.biomedcentral.com/1471-230X/4/3
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chronic hepatitis C patients with elevated ALT in case III.
Twenty-one point eight percent of them recommended
either IFN-α or lamivudine to treat chronic viral hepatitis
B in case II. The remainder GPs did not actually know
what to do with such patients. Therefore the knowledge of
treatment options in chronic hepatitis B and C is poor,
this may decrease the ability to accurately assess patients
and initiate therapy. This clearly identifies that regular
updates on current treatments are needed. Protocols,
reviews and consensus reports have been useful in the
management of chronic viral hepatitis [17-19].
General practitioners reported medical books and jour-
nals to be the most useful source of information regarding
viral hepatitis but were concerned about inadequate
timely access the journal and also the low rate of obtain-
ing information from on-line sites. However internet may
be a solution for difficulties and delays in obtaining rele-
vant information. Most of the updated guidelines and
consensus reports could be easily and freely accessible at




As the "gatekeepers" to the health care system, GPs carry
out significant missions in PHCCs where primary protec-
tive and curative health services are held out. It is, there-
fore necessary to completely inform GPs of common
health problems as well as of the ways of their solutions.
In order to prevent HBV and HCV infections, GPs drive
great responsibility of the diagnosis and treatment of the
infected patients as well as their follow up. This study
demonstrates high awareness of the transmission of viral
hepatitis and high-risk groups among GPs but also con-
siderable knowledge gaps about the timing of ordering
diagnostic tests and treatment recommendations. Results
suggest several opportunities for improvement. Efforts to
educate the GPs about the appropriateness and impor-
tance of identification of HBV and HCV infection during
post-graduation period should be improved. PHCCs
should be technically supported to ease the diagnosis of
HBV and HCV infections. Finally further coordination
between an advanced health care center and specialists
should be established to enable such infections to be fol-
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Table 2: Management of Patients with HCV
Case III Case IV
n % Current Advice n % Current Advice
At this point your next step would be to:
Repeat the measurement of anti-HCV 16 12.4 No 49 38 No
Follow in clinic: refer if symptoms develop 5 3.9 No 30 23.2 Yes
Refer to a specialist 108 83.7 Yes 50 38.8 Yes
Don't know - - - -
Which additional tests would you order 
(check all that apply)*:
anti-HCV ELISA 52 40.3 No 50 38.8 No
anti-HCV RIBA 2 1.6 Yes 4 3.1 Yes
HCV-RNA by PCR 105 81.4 Yes 106 82.2 Yes
HCV genotyping 3 2.3 No 9 7.0 No
If you order therapy, which regimen 
would you recommend:
IFN-α for 6 months 23 17.8 No 20 15.5 No
IFN-α for 12 months 4 3.1 No 4 3.1 No
Ribavirin alone - - No - - No
IFN-α and Ribavirin 23 17.8 Yes 24 18.6 No
Don't know 79 61.3 81 62.8
* The sum of the answer is higher than the number of the participants for the participants checked more than one item.Publish with BioMed Central    and   every 
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